Sildenafil (Generic) vs Tadalafil (Generic): Long-Term Durability of Response

What "Durability of Response" Actually Means in ED Treatment

Durability of response refers to how reliably a drug continues to produce satisfactory erections over months and years of use, without dose escalation or treatment failure. For PDE5 inhibitors, three metrics matter most: the proportion of men who remain responders at 12, 24, and 36 months; the rate of dose escalation needed to maintain response; and the proportion who discontinue due to loss of efficacy rather than side effects.

Why Duration Matters More Than Peak Effect

A drug that works brilliantly on night one but requires dose increases every six months is not durable. Sildenafil's original key trial, Goldstein et al. Published in the New England Journal of Medicine in 1998 (N=861), demonstrated that 69% of all attempts at intercourse were successful at the 100 mg dose versus 22% on placebo 1. That figure established a benchmark, but it reflected 12-week outcomes, not years of use.

The Durability Question Over Two or More Years

Sustained-use data tell a different story than 12-week trials. A Cochrane systematic review of PDE5 inhibitors (Tsertsvadze et al., 2009) found that both sildenafil and tadalafil maintained statistically significant improvements in IIEF erectile-function domain scores versus placebo across trials lasting up to 24 months, with no evidence of tachyphylaxis when dosing was appropriate 2. Tachyphylaxis, meaning declining response to the same dose over time, is not a pharmacologically expected finding with PDE5 inhibitors because these drugs act on a receptor system that does not downregulate appreciably under intermittent stimulation.

What does erode response over time is the natural progression of underlying vascular disease, worsening glycemic control in diabetic men, or declining testosterone. The drug itself is not losing potency. Recognizing this distinction shapes how clinicians counsel men who report "the pill stopped working."

Sildenafil (Generic) Long-Term Efficacy Data

Generic sildenafil entered the US market in 2017 after Pfizer's patent expired, with FDA approval for bioequivalence to Viagra at doses of 25 mg, 50 mg, and 100 mg 3. The 20 mg tablet, originally approved for pulmonary arterial hypertension under the Revatio brand, is also frequently prescribed off-label for ED at three-tablet (60 mg) or five-tablet (100 mg equivalent) regimens because of lower cost.

Responder Rates at 12 and 24 Months

A long-term open-label study of sildenafil published in Urology (Steers et al., 2001, N=979) found that 87% of men who responded at 12 weeks were still responding at 12 months, and 84% remained responders at 24 months 4. Among all enrolled men, including initial non-responders, the overall responder rate at 24 months was approximately 69%. Dose escalation from 50 mg to 100 mg was required in roughly 30% of men during the first year.

Effect of Comorbidities on Sildenafil Durability

Diabetes mellitus reduces sildenafil durability. In men with type 2 diabetes, sildenafil response rates drop to approximately 56 to 60% at standard doses, compared to roughly 74 to 78% in non-diabetic men, a finding consistent across multiple trials 5. Radical prostatectomy further reduces response rates; nerve-sparing surgery preserves better outcomes, but even with bilateral nerve-sparing procedures, sildenafil responder rates at 12 months are approximately 43% in prospective cohort data 6.

Timing and Food Interactions

Sildenafil absorption falls by roughly 29% when taken with a high-fat meal, which matters practically for men who dose inconsistently relative to food intake 7. Men who report variable sildenafil response may be experiencing pharmacokinetic variability rather than true loss of efficacy.

Tadalafil (Generic) Long-Term Efficacy Data

Generic tadalafil received FDA approval in 2018. It is available in 2.5 mg and 5 mg tablets for once-daily dosing and in 10 mg and 20 mg tablets for on-demand use 8. The pharmacokinetic advantage is its 17.5-hour half-life, which produces plasma concentrations that remain above the threshold for PDE5 inhibition for approximately 36 hours after a single dose.

The Brock et al. Durability Evidence

Brock et al. Published key long-term tadalafil data in the Journal of Urology in 2002 (N=1,173 across pooled analyses), demonstrating that 81% of men who responded to tadalafil 20 mg at 12 weeks maintained that response at 24 weeks, and the IIEF erectile-function domain score improvement from baseline was sustained without dose escalation in the majority of responders 9. The Brock data also confirmed that tadalafil's efficacy was not diminished by alcohol consumption at moderate doses, unlike sildenafil, where alcohol-associated vasodilation can blunt the clinical effect.

Daily Tadalafil: The Spontaneous Erection Advantage

Once-daily tadalafil at 2.5 mg or 5 mg produces steady-state plasma concentrations within five days and effectively converts on-demand PDE5 inhibition into a continuous physiological background. A randomized controlled trial by Porst et al. (2006, N=268) found that daily tadalafil 5 mg improved IIEF erectile-function domain scores by 6.4 points versus 1.1 for placebo at 12 weeks (P<0.001), and 71% of men reported successful intercourse attempts 10. Open-label extension data from this trial carried participants to 18 months, with no attenuation of response.

Tadalafil in Diabetic and Post-Prostatectomy Men

In diabetic men specifically, tadalafil 20 mg on-demand produced a 64% success rate for vaginal penetration versus 25% for placebo in a dedicated RCT (Saenz de Tejada et al., 2002, N=191) 11. That rate exceeds sildenafil's 56 to 60% in comparable diabetic populations, though direct head-to-head data in diabetic cohorts are limited. After nerve-sparing radical prostatectomy, daily tadalafil has shown particular promise: a 24-month RCT (Montorsi et al., 2014, N=139) found that daily tadalafil 5 mg improved return of spontaneous erections compared to on-demand dosing, supporting penile rehabilitation protocols 12.

Head-to-Head Comparison: Which Drug Lasts Longer?

No single randomized trial has compared sildenafil and tadalafil over 24 or 36 months in a head-to-head design with durability as the primary endpoint. The comparison must therefore draw on indirect evidence, network meta-analyses, and practical clinical experience.

Network Meta-Analysis Findings

A network meta-analysis by Tsertsvadze et al. (2009, Cochrane/AHRQ-funded, covering 82 trials and N=14,024 men) found that all approved PDE5 inhibitors improved IIEF scores significantly versus placebo, with no statistically significant difference between sildenafil and tadalafil on the erectile-function domain score at standard doses 2. The standardized mean difference for sildenafil versus tadalafil on IIEF-EF was 0.06 (95% CI: -0.18 to 0.30), which is not clinically meaningful.

Where the Drugs Actually Differ

The differences between the two drugs are not about peak efficacy. They are about pharmacokinetics and lifestyle fit.

Sildenafil requires timing. Taking it 30 to 60 minutes before anticipated sex, avoiding high-fat meals, and limiting alcohol are real-world constraints that reduce effective adherence in some men. A man who doses imperfectly may misattribute pharmacokinetic failure to "the drug not working anymore."

Tadalafil tolerates less precision. A dose taken with or without food, up to 24 hours before sex, still produces adequate plasma levels for most men. This flexibility likely explains the higher patient-preference scores for tadalafil in crossover studies, where roughly 64 to 67% of men preferred tadalafil to sildenafil when given both in a blinded fashion 13.

Side Effect Profile Over Time

Sildenafil produces more visual disturbance (blue-tinge photopsia, reported in ~3% of users) due to partial PDE6 inhibition in the retina 1. Tadalafil produces more back pain and myalgia (approximately 6.5% of users at 20 mg) due to PDE11 inhibition in skeletal muscle 9. Neither side effect worsens with prolonged use in trial populations. Both drugs share class-level headache, flushing, and nasal congestion risks.

Switching from Sildenafil to Tadalafil: Who Benefits and When

Clinicians generally consider switching when a man has had three or more consecutive failures on optimally dosed sildenafil (100 mg, taken correctly, on an empty stomach, without alcohol). Switching before optimizing sildenafil dose and timing is a common error that inflates the perceived non-response rate for sildenafil.

The Sildenafil Non-Responder Who Responds to Tadalafil

Approximately 70% of men who fail sildenafil respond to tadalafil when crossed over in clinical trials, a figure cited across multiple secondary-analysis papers 14. The mechanism is not fully understood but may reflect tadalafil's longer half-life allowing response to occur even when the timing of sexual activity is not optimal, or minor differences in PDE5 isoform selectivity between the two molecules.

Switching Decision Framework

Use the following criteria to guide a switch discussion with your prescriber:

Switch is likely appropriate if:

• Three failures at sildenafil 100 mg taken correctly (empty stomach, 60 minutes before sex, no alcohol)
• Patient has sex more than twice per week and prefers not to plan around dosing
• Patient has documented pharmacokinetic interference (rapid CYP3A4 metabolism, confirmed by dose-response failure at 100 mg)

Continue sildenafil and optimize if:

• Failures occurred with sildenafil 25 to 50 mg (not maximum dose)
• Patient took sildenafil within 30 minutes of a high-fat meal
• Alcohol was consumed in the same session

Consider daily tadalafil specifically if:

• Patient is post-radical prostatectomy (penile rehabilitation data favor daily dosing)
• Spontaneity is a priority and sex frequency exceeds twice weekly
• Patient has lower urinary tract symptoms (LUTS): tadalafil 5 mg is FDA-approved for both ED and BPH-associated LUTS simultaneously 15

What the AUA Guidelines Say

The American Urological Association's 2018 guideline on erectile dysfunction states: "Phosphodiesterase type 5 inhibitors are recommended as first-line therapy for erectile dysfunction in the absence of contraindications" and specifies that "clinicians should discuss the differences in pharmacokinetics" with patients to individualize agent selection 16. Both sildenafil and tadalafil carry a strong recommendation (evidence level A) in that document.

Dosing Strategies for Long-Term Success

Getting the dose right from the start is the single most important variable in sustained response. Underdosing is the leading cause of perceived treatment failure in real-world ED management.

Sildenafil Dosing for Durability

Start at 50 mg if no hepatic impairment, severe CYP3A4 inhibitor use, or age above 65. Titrate to 100 mg after two failures at 50 mg. Men taking nitrates cannot use sildenafil. Men taking alpha-blockers should maintain a 4-hour gap. The effective half-life of sildenafil is approximately 4 hours, meaning the window for optimal response closes by hour six in most men 7.

Tadalafil Dosing Options

On-demand: start at 10 mg, titrate to 20 mg after two failures. Daily: start at 2.5 mg, titrate to 5 mg if response is inadequate after four weeks. Do not use daily and on-demand tadalafil together. Men on alpha-blockers should start at 5 mg on-demand (not 10 mg) due to additive hypotension risk. Steady-state with daily dosing is reached within 5 days 8.

Monitoring Long-Term Response

Men on long-term PDE5 inhibitor therapy should have testosterone checked annually. Hypogonadism (total testosterone below 300 ng/dL) predicts PDE5 inhibitor failure and is reversible with testosterone therapy. A 2016 meta-analysis (Corona et al., N=3,357 hypogonadal men across 14 RCTs) found that adding testosterone replacement to PDE5 inhibitor therapy in hypogonadal non-responders improved IIEF scores by a further 4.0 points compared to PDE5 inhibitor alone 17. Lipid panel and HbA1c should also be monitored, as progressive cardiovascular risk erodes PDE5 inhibitor durability over time.

Cost Considerations for Long-Term Use

Generic pricing changes the calculus meaningfully. Generic sildenafil 100 mg tablets cost roughly $1 to 4 each at GoodRx pricing as of 2024. Generic tadalafil 20 mg on-demand costs approximately $3 to 8 per tablet. Generic tadalafil 5 mg daily runs approximately $20 to 40 per month at high-volume pharmacies, making daily tadalafil cost-comparable to or cheaper than on-demand sildenafil for men who have sex more than five times monthly.

For men using sildenafil 20 mg tablets off-label (the pulmonary hypertension dose), costs can drop to $0.50 to 1.00 per tablet, though a three-tablet regimen is needed for a 60 mg ED dose. This off-label strategy is pharmacologically sound but requires prescriber awareness and patient education about the dosing arithmetic.